Spero Therapeutics/SPRO

$1.56

-
-
1D1W1MYTD1YMAX

About Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.

Ticker

SPRO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Satyavrat Shukla

Employees

46

Headquarters

Cambridge, United States

SPRO Metrics

BasicAdvanced
$86M
Market cap
3.77
P/E ratio
$0.42
EPS
0.67
Beta
-
Dividend rate
$86M
0.67011
$1.94
$0.99
311K
3.351
0.144
16.7%
29.06%
21.73%
3.774
0.772
0.89
0.89
107.4%
146.84%
123.23%

What the Analysts think about SPRO

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 2 analysts.
380.77% upside
High $8.00
Low $7.00
$1.56
Current price
$7.50
Average price target

SPRO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-136.95% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.2M
-87.48%
Net income
-$13M
-124.66%
Profit margin
-136.95%
-296.99%

SPRO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 453.85%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.23
-$0.06
$0.96
-$0.24
-
Expected
-$0.34
-$0.03
-$0.10
-$0.04
-$0.38
Surprise
-33.01%
100%
-1,060%
453.85%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Spero Therapeutics stock?

Spero Therapeutics (SPRO) has a market cap of $86M as of May 22, 2024.

What is the P/E ratio for Spero Therapeutics stock?

The price to earnings (P/E) ratio for Spero Therapeutics (SPRO) stock is 3.77 as of May 22, 2024.

Does Spero Therapeutics stock pay dividends?

No, Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next Spero Therapeutics dividend payment date?

Spero Therapeutics (SPRO) stock does not pay dividends to its shareholders.

What is the beta indicator for Spero Therapeutics?

Spero Therapeutics (SPRO) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Spero Therapeutics stock price target?

The target price for Spero Therapeutics (SPRO) stock is $7.5, which is 396.69% above the current price of $1.51. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Spero Therapeutics stock

Buy or sell Spero Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing